Simplicity Solutions LLC Has $46,000 Stock Position in Precigen, Inc. (NASDAQ:PGEN)

Simplicity Solutions LLC decreased its position in Precigen, Inc. (NASDAQ:PGEN) by 23.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 34,245 shares of the biotechnology company’s stock after selling 10,731 shares during the period. Simplicity Solutions LLC’s holdings in Precigen were worth $46,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in PGEN. Advisor Group Holdings Inc. raised its holdings in Precigen by 35.5% in the 1st quarter. Advisor Group Holdings Inc. now owns 182,739 shares of the biotechnology company’s stock valued at $389,000 after acquiring an additional 47,925 shares in the last quarter. Swiss National Bank raised its holdings in shares of Precigen by 7.2% in the 1st quarter. Swiss National Bank now owns 220,000 shares of the biotechnology company’s stock worth $464,000 after buying an additional 14,700 shares in the last quarter. Bank of Montreal Can acquired a new position in shares of Precigen in the 1st quarter worth approximately $449,000. BlackRock Inc. raised its holdings in shares of Precigen by 0.6% in the 1st quarter. BlackRock Inc. now owns 7,225,641 shares of the biotechnology company’s stock worth $15,246,000 after buying an additional 46,196 shares in the last quarter. Finally, Synovus Financial Corp raised its holdings in shares of Precigen by 30.2% in the 1st quarter. Synovus Financial Corp now owns 51,690 shares of the biotechnology company’s stock worth $109,000 after buying an additional 12,000 shares in the last quarter. Institutional investors and hedge funds own 33.51% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on PGEN. JMP Securities reissued a “market outperform” rating and issued a $14.00 target price on shares of Precigen in a report on Wednesday, March 20th. HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of Precigen in a report on Wednesday, March 20th. JPMorgan Chase & Co. cut Precigen from a “neutral” rating to an “underweight” rating in a report on Friday, March 22nd. Finally, StockNews.com raised Precigen to a “sell” rating in a report on Tuesday, March 26th.

Precigen Stock Performance

NASDAQ PGEN opened at $1.33 on Monday. Precigen, Inc. has a one year low of $0.84 and a one year high of $1.88. The stock’s 50 day simple moving average is $1.46 and its 200 day simple moving average is $1.31.

Precigen (NASDAQ:PGEN) last released its quarterly earnings results on Tuesday, March 19th. The biotechnology company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). The business had revenue of $1.23 million for the quarter, compared to the consensus estimate of $2.03 million. Precigen had a negative return on equity of 55.47% and a negative net margin of 1,540.63%. As a group, equities research analysts forecast that Precigen, Inc. will post -0.33 EPS for the current fiscal year.

Precigen Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.